The molecular tool CRISPR-Cas9 can be used to treat inherited blood disorders, but this may cause unintended genetic alterations. A team led by MDC researchers Klaus Rajewsky and Van Trung Chu has now presented an approach in Science Advances that minimizes such adverse consequences.
Click here for original story, A fine-tuned gene editor that minimizes adverse consequences
Source: Phys.org